An oncology biotech that promises individualized immunotherapies is part of the slate for the week.
The IPO Terms
Germany-based BioNTecg SE is proposing to offer 13.2 million ADSs, each ADS representing an ordinary share, in an IPO, according to a F-1/A filing. The company expects to price the offering between $18 and $20 per ADS.
At the midpoint of the estimated price range, the size of the offering is likely to be $250.8 million.
The company has applied for listing its shares on the Nasdaq under the ticker symbol "BNTX."
JPMorgan, Bank of America Merrill Lynch, UBS and SVB Leerink are the lead managers for the offering, while Canaccord Genuity, Bryan, Garnier & Co, and Berenberg are serving as co-managers.
Founded in 2008, BioNTech uses a combination of immunology, cutting-edge therapeutics platforms and a suite of patient profiling and bioinformatic tools to develop individualized immunotherapies for cancer as well as other diseases.
Its product candidates are developed using numerous immunotherapeutic platforms across four drug classes, namely mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators.
The company has established relationships with seven biopharma companies, including Roche Holdings AG Basel ADR (OTC: RHHBY)'s Genentech, Sanofi SA (NASDAQ: SNY), GENMAB A/S/S ADR (NASDAQ: GMAB), Genevant Sciences, Eli Lilly And Co (NYSE: LLY), Bayer AG (OTC: BAYRY) and Pfizer Inc. (NYSE: PFE), which provide with R&D assistance and non-dilutive capital.
BioNTech reported revenues from contracts of 127.58 million euros in 2018, up about 107% year-over-year. The loss for the year narrowed from 85.65 million euros to 48.02 million euros.
For the six months ended June 30, revenues from contracts rose roughly 20% to 51.94 million euros but the loss widened from 23.24 million euros in 2018 to 90.73 million in 2019.
See more from Benzinga
- The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration
- Former Nasdaq CEO On IPO Debacle: Companies Need To Show Path To Profitability
- AMD Unveils Budget Radeon Graphics Cards Aimed At Nvidia's Entry-Level Products
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.